AU2003257770A1 - Replicability virus which can express anti-tumour antibody with high efficiency and the use of it - Google Patents

Replicability virus which can express anti-tumour antibody with high efficiency and the use of it

Info

Publication number
AU2003257770A1
AU2003257770A1 AU2003257770A AU2003257770A AU2003257770A1 AU 2003257770 A1 AU2003257770 A1 AU 2003257770A1 AU 2003257770 A AU2003257770 A AU 2003257770A AU 2003257770 A AU2003257770 A AU 2003257770A AU 2003257770 A1 AU2003257770 A1 AU 2003257770A1
Authority
AU
Australia
Prior art keywords
high efficiency
express anti
tumour antibody
replicability
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003257770A
Inventor
Qijun Qian
Qin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SINO-GENE BIOTECHNOLOGY Ltd
Original Assignee
SINO GENE BIOTECHNOLOGY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SINO GENE BIOTECHNOLOGY Ltd filed Critical SINO GENE BIOTECHNOLOGY Ltd
Publication of AU2003257770A1 publication Critical patent/AU2003257770A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003257770A 2002-07-15 2003-07-15 Replicability virus which can express anti-tumour antibody with high efficiency and the use of it Abandoned AU2003257770A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNA021360286A CN1468956A (en) 2002-07-15 2002-07-15 Recombinant virus of antibody for high-efficiency expression to treat tumor and its use
CN02136028.6 2002-07-15
PCT/CN2003/000565 WO2004007703A1 (en) 2002-07-15 2003-07-15 Replicability virus which can express anti-tumour antibody with high efficiency and the use of it

Publications (1)

Publication Number Publication Date
AU2003257770A1 true AU2003257770A1 (en) 2004-02-02

Family

ID=29784631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003257770A Abandoned AU2003257770A1 (en) 2002-07-15 2003-07-15 Replicability virus which can express anti-tumour antibody with high efficiency and the use of it

Country Status (3)

Country Link
CN (1) CN1468956A (en)
AU (1) AU2003257770A1 (en)
WO (1) WO2004007703A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1542132A (en) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 Highly expressed recombinant virus containing human constant region all-antibody gene and its use for treating tumor
CN1528887A (en) * 2003-10-15 2004-09-15 中国科学院上海生命科学研究院 Tumour targeting bigene-virus structure method
CN105132439A (en) * 2006-07-28 2015-12-09 宾夕法尼亚大学托管会 Improved vaccines and methods for using the same
CN100444895C (en) * 2006-12-05 2008-12-24 广州市恺泰生物科技有限公司 Immunomodulator for treating malignant tumor
CN101497665B (en) * 2009-02-25 2013-02-06 厦门大学 Human fiber plasminogen Kringle5 polyclonal antibody, and preparation and use thereof
CN104558194B (en) * 2013-10-17 2018-04-27 泰州迈博太科药业有限公司 A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
CN104877969A (en) * 2014-12-14 2015-09-02 刘滨磊 Recombinant oncolytic II-type herpes simplex virus (HSV) and pharmaceutical composition thereof
CN109913425B (en) * 2019-03-22 2021-05-11 中国人民解放军总医院第五医学中心 Recombinant influenza virus rescue method and application thereof in tumor treatment
CN113249342B (en) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 Chimeric broad-spectrum oncolytic adenovirus with multiple mechanism synergistic and synergistic immunotherapy and application thereof in tumor treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018866A1 (en) * 1994-01-11 1995-07-13 Manson Lionel A Method of determining tumor immunogenicity
CN1390233A (en) * 1999-07-23 2003-01-08 马萨诸塞州大学 Antitumor antibodies, proteins, and uses thereof

Also Published As

Publication number Publication date
CN1468956A (en) 2004-01-21
WO2004007703A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
AU2002234653A1 (en) Aluminium and hexamethylenetetramine complex and the applications thereof
AU2003263759A1 (en) Heat sink made from longer and shorter graphite sheets
ATE464068T1 (en) ANTIBODIES AGAINST OPGL
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
IL172871A0 (en) Rg1 antibodies and uses thereof
EP1787998A4 (en) Antibody and utilization of the same
HK1091132A1 (en) Anti-cd33 antibodies and the use thereof -cd33
EP1551447A4 (en) Anti-addl antibodies and uses thereof
EP1627185A4 (en) Trapped vortex combustor
GB0206359D0 (en) Viral antigens
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
AU2003301066A1 (en) Al2o3-la2o3-y2o3-mgo ceramics, and methods of making the same
DK1523329T3 (en) Virus particle adjuvant
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
AU2003218099A1 (en) Modulation of the immune response through the manipulation of arginine levels
AU2003303926A1 (en) Ceramics and methods of making the same
EP1664230A4 (en) Hydrophobic composites and particulates and applications thereof
AU2003257770A1 (en) Replicability virus which can express anti-tumour antibody with high efficiency and the use of it
WO2004031352A3 (en) Interferon variants with improved properties
IL172510A0 (en) Antibodies and uses thereof
AU2003298129A1 (en) Floor-furnace chimney and the use thereof
AU2003268145A1 (en) Methods for propagating adenovirus and virus produced thereby
AU2003293424A1 (en) File with high-traction surface
WO2006119337A8 (en) Fluorescent proteins and uses thereof
EP1534332A4 (en) Antibodies and uses thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase